{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:49:39Z","timestamp":1791352179005,"version":"4.3.1"},"reference-count":204,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.pharmthera.2010.02.006","type":"journal-article","created":{"date-parts":[[2010,3,15]],"date-time":"2010-03-15T09:35:20Z","timestamp":1268645720000},"page":"263-278","source":"Crossref","is-referenced-by-count":38,"title":["Molecular pathways and agents for lowering LDL-cholesterol in addition to statins"],"prefix":"10.1016","volume":"126","author":[{"given":"Philippe","family":"Costet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2010.02.006_bib1","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1161\/01.ATV.0000181761.16341.2b","article-title":"Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine","volume":"25","author":"Abidi","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1172\/JCI9021","article-title":"Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1","volume":"105","author":"Accad","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0016-5085(82)90305-5","article-title":"National Cooperative Gallstone Study: the effect of chenodeoxycholic acid on lipoproteins and apolipoproteins","volume":"82","author":"Albers","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib5","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1126\/science.1093131","article-title":"Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption","volume":"303","author":"Altmann","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib6","doi-asserted-by":"crossref","first-page":"20420","DOI":"10.1074\/jbc.M302505200","article-title":"Syndecan-1 expression is regulated in an isoform-specific manner by the farnesoid-X receptor","volume":"278","author":"Anisfeld","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib7","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1006\/bbrc.1998.9174","article-title":"Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene","volume":"249","author":"Bakker","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib8","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nrd2830","article-title":"Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes","volume":"8","author":"Baxter","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib9","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.amjcard.2005.11.039","article-title":"Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia","volume":"97","author":"Bays","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib10","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1161\/01.ATV.0000225289.30767.06","article-title":"Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor\u2212\/\u2212 mice","volume":"26","author":"Bell","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib11","doi-asserted-by":"crossref","first-page":"48865","DOI":"10.1074\/jbc.M409699200","article-title":"NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the Low Density Lipoprotein (LDL) Receptor and LDL cholesterol","volume":"279","author":"Benjannet","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib13","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1126\/science.290.5497.1771","article-title":"Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters","volume":"290","author":"Berge","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1073\/pnas.0705286104","article-title":"The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans","volume":"105","author":"Berkenstam","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib15","doi-asserted-by":"crossref","first-page":"E716","DOI":"10.1152\/ajpendo.00355.2005","article-title":"Activation of the farnesoid X receptor improves lipid metabolism in combined hyperlipidemic hamsters","volume":"290","author":"Bilz","year":"2006","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib16","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0002-9149(00)00976-0","article-title":"Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy","volume":"86","author":"Blair","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib17","doi-asserted-by":"crossref","first-page":"11374","DOI":"10.1074\/jbc.M710457200","article-title":"Regulation of ApoB secretion by the LDL receptor requires exit from the endoplasmic reticulum and interaction with ApoE or ApoB","volume":"283","author":"Blasiole","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib18","doi-asserted-by":"crossref","first-page":"16394","DOI":"10.1016\/S0021-9258(18)49269-1","article-title":"Intrahepatic assembly of very low density lipoproteins. Rate of transport out of the endoplasmic reticulum determines rate of secretion","volume":"262","author":"Borchardt","year":"1987","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib19","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0022-2275(20)33370-8","article-title":"Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry","volume":"40","author":"Bosner","year":"1999","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib20","doi-asserted-by":"crossref","first-page":"9197","DOI":"10.1074\/jbc.272.14.9197","article-title":"Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol","volume":"272","author":"Bostedor","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib21","doi-asserted-by":"crossref","first-page":"10522","DOI":"10.1074\/jbc.M707659200","article-title":"Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss","volume":"283","author":"Brown","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib22","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nutres.2008.02.003","article-title":"Phytosterols: physiologic and metabolic aspects related to cholesterol-lowering properties","volume":"28","author":"Brufau","year":"2008","journal-title":"Nutr Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib23","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI27352","article-title":"Intestinal ABCA1 directly contributes to HDL biogenesis in vivo","volume":"116","author":"Brunham","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/82153","article-title":"Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice","volume":"6","author":"Buhman","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib25","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib26","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1079\/BJN20051659","article-title":"Phytosterol-mediated inhibition of intestinal cholesterol absorption is independent of ATP-binding cassette transporter A1","volume":"95","author":"Calpe-Berdiel","year":"2006","journal-title":"Br J Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib27","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.atherosclerosis.2006.11.042","article-title":"Are LXR-regulated genes a major molecular target of plant sterols\/stanols?","volume":"195","author":"Calpe-Berdiel","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2008.02.004","article-title":"Berberine decreases PCSK9 expression in HepG2 cells","author":"Cameron","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib29","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib30","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1161\/ATVBAHA.109.194191","article-title":"PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia","volume":"29","author":"Cariou","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib31","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib32","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.coph.2004.11.004","article-title":"Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy","volume":"5","author":"Chinetti-Gbaguidi","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib34","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1021\/jm960405n","article-title":"2-Azetidinone cholesterol absorption inhibitors: structure-activity relationships on the heterocyclic nucleus","volume":"39","author":"Clader","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib35","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0016-5085(03)00896-5","article-title":"Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression","volume":"125","author":"Claudel","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib36","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib37","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.tibs.2008.06.005","article-title":"PCSK9 and LDL cholesterol: unravelling the target to design the bullet","volume":"33","author":"Costet","year":"2008","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa061189","article-title":"Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia","volume":"356","author":"Cuchel","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib39","doi-asserted-by":"crossref","first-page":"10453","DOI":"10.1074\/jbc.M709460200","article-title":"Identification of the interaction site within acyl-CoA:cholesterol acyltransferase 2 for the isoform-specific inhibitor pyripyropene A","volume":"283","author":"Das","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib40","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib41","doi-asserted-by":"crossref","first-page":"33586","DOI":"10.1074\/jbc.M405817200","article-title":"Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis","volume":"279","author":"Davis","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib42","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1017\/S0007114508966113","article-title":"Effects of long-term plant sterol or stanol ester consumption on lipid and lipoprotein metabolism in subjects on statin treatment","volume":"100","author":"de Jong","year":"2008","journal-title":"Br J Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib43","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/j.jacc.2008.03.016","article-title":"Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches","volume":"51","author":"deGoma","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3945\/jn.108.095125","article-title":"Continuous dose\u2013response relationship of the LDL-cholesterol-lowering effect of phytosterol intake","volume":"139","author":"Demonty","year":"2009","journal-title":"J Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib45","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1053\/gast.2001.23250","article-title":"ATP-binding cassette transporter A1 (ABCA1) affects total body sterol metabolism","volume":"120","author":"Drobnik","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/me.16.1.14","article-title":"A distinct thyroid hormone response element mediates repression of the human cholesterol 7alpha-hydroxylase (CYP7A1) gene promoter","volume":"16","author":"Drover","year":"2002","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib47","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1091\/mbc.E05-11-1094","article-title":"Involvement of Akt in ER-to-Golgi transport of SCAP\/SREBP: a link between a key cell proliferative pathway and membrane synthesis","volume":"17","author":"Du","year":"2006","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib48","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1042\/BJ20082407","article-title":"Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor","volume":"419","author":"Duff","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib50","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","article-title":"Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia","volume":"90","author":"Dujovne","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib51","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S0022-2275(20)41990-X","article-title":"Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia","volume":"32","author":"Elmberger","year":"1991","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib52","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","author":"Endo","year":"1992","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib53","doi-asserted-by":"crossref","first-page":"15490","DOI":"10.1073\/pnas.0702759104","article-title":"Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index","volume":"104","author":"Erion","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib54","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","author":"Expert Panel","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib55","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ijpharm.2008.06.011","article-title":"State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers","volume":"364","author":"Fattal","year":"2008","journal-title":"Int J Pharm"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib56","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1194\/jlr.M400208-JLR200","article-title":"Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression","volume":"45","author":"Field","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib57","doi-asserted-by":"crossref","first-page":"17377","DOI":"10.1074\/jbc.R100068200","article-title":"Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins","volume":"277","author":"Fisher","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib58","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib59","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1194\/jlr.M300403-JLR200","article-title":"Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells","volume":"45","author":"Ganji","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib60","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-121-6-199409150-00004","article-title":"Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial","volume":"121","author":"Garg","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib61","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.cmet.2008.04.001","article-title":"The cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1","volume":"7","author":"Ge","year":"2008","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib62","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2008.10.025","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia","volume":"103","author":"Goldberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib64","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/ATVBAHA.108.179564","article-title":"The LDL receptor","volume":"29","author":"Goldstein","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib65","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1161\/01.ATV.17.11.2707","article-title":"Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts","volume":"17","author":"Goto","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2007.08.024","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: executive summary","volume":"194","author":"Graham","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib67","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1194\/jlr.C600025-JLR200","article-title":"Antisense inhibition of proprotein convertase subtilisin\/kexin type 9 reduces serum LDL in hyperlipidemic mice","volume":"48","author":"Graham","year":"2007","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib68","doi-asserted-by":"crossref","first-page":"10067","DOI":"10.1073\/pnas.1633737100","article-title":"Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability","volume":"100","author":"Grover","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib69","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","article-title":"Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines","volume":"110","author":"Grundy","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib70","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib71","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1161\/01.ATV.16.6.763","article-title":"Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia","volume":"16","author":"Guerin","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib72","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1210\/me.14.11.1739","article-title":"Thyroid hormone receptor beta-deficient mice show complete loss of the normal cholesterol 7alpha-hydroxylase (CYP7A) response to thyroid hormone but display enhanced resistance to dietary cholesterol","volume":"14","author":"Gullberg","year":"2000","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib73","first-page":"19774436","article-title":"Very high plant stanol intake and serum plant stanols and non-cholesterol sterols","author":"Gylling","year":"2009","journal-title":"Eur J Nutr PMID"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib74","first-page":"19","article-title":"LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects","volume":"12","author":"Gylling","year":"2002","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib75","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib76","first-page":"1","article-title":"Intake estimates of naturally occurring phytosterols using deterministic and probabilistic methods in a representative Irish population","author":"Hearty","year":"2008","journal-title":"Int J Food Sci Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib77","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1101\/gad.1083503","article-title":"Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis","volume":"17","author":"Holt","year":"2003","journal-title":"Genes Dev"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib78","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/bjp.2008.331","article-title":"Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor","volume":"155","author":"Huang","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib80","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3177\/jnsv.35.361","article-title":"Effects of sitosterol and sitostanol on micellar solubility of cholesterol","volume":"35","author":"Ikeda","year":"1989","journal-title":"J Nutr Sci Vitaminol (Tokyo)"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cmet.2005.09.001","article-title":"Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis","volume":"2","author":"Inagaki","year":"2005","journal-title":"Cell Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib82","first-page":"19828909","article-title":"Baseline cholesterol absorption and the response to ezetimibe\/simvastatin therapy; a post-hoc analysis of the ENHANCE trial","author":"Jakulj","year":"2009","journal-title":"J Lipid Res PMID"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1146\/annurev.biochem.74.082803.133354","article-title":"Structure and physiologic function of the low-density lipoprotein receptor","volume":"74","author":"Jeon","year":"2005","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib84","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1161\/01.ATV.19.4.1051","article-title":"Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells","volume":"19","author":"Jin","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib85","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study","volume":"204","author":"Jones","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib86","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1172\/JCI29415","article-title":"Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemia","volume":"117","author":"Jones","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib87","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0022-2275(20)32378-6","article-title":"Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters","volume":"41","author":"Jones","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib88","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/ncpcardio1251","article-title":"Microsomal triglyceride transfer protein inhibition-friend or foe?","volume":"5","author":"Joy","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib89","doi-asserted-by":"crossref","first-page":"36091","DOI":"10.1074\/jbc.M304153200","article-title":"Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist","volume":"278","author":"Kaneko","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib90","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1210\/me.15.10.1720","article-title":"Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids","volume":"15","author":"Kast","year":"2001","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib91","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib92","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1161\/CIRCULATIONAHA.105.606442","article-title":"Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B","volume":"114","author":"Kastelein","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib93","doi-asserted-by":"crossref","first-page":"965","DOI":"10.4065\/78.8.965","article-title":"Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels","volume":"78","author":"Katan","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib94","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.bbrc.2005.01.139","article-title":"Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1","volume":"329","author":"Katsuma","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib95","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib96","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/S0140-6736(09)61047-3","article-title":"Recent developments in hyperthyroidism","volume":"373","author":"Kharlip","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib97","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/sj.ejcn.1602765","article-title":"Food sources of plant sterols in the EPIC Norfolk population","volume":"62","author":"Klingberg","year":"2008","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib98","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0002-9343(01)00638-6","article-title":"Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia","volume":"110","author":"Knapp","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib99","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm1135","article-title":"Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins","volume":"10","author":"Kong","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-2275(20)32079-4","article-title":"Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade","volume":"41","author":"Kotzka","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib102","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.atherosclerosis.2009.02.012","article-title":"Cellular and secreted pro-protein convertase subtilisin\/kexin type 9 catalytic activity in hepatocytes","volume":"206","author":"Kourimate","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib103","doi-asserted-by":"crossref","first-page":"9666","DOI":"10.1074\/jbc.M705831200","article-title":"Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin\/kexin type 9","volume":"283","author":"Kourimate","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib104","first-page":"184","article-title":"Efficacy and safety of micronised fenofibrate in a randomised double-blind study comparing four doses from 200mg to 400mg daily with placebo in patients with hypercholesterolemia","volume":"26","author":"Krempf","year":"2000","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib105","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.3748\/wjg.v12.i40.6429","article-title":"Emerging roles of the intestine in control of cholesterol metabolism","volume":"12","author":"Kruit","year":"2006","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib106","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1210\/en.2006-0098","article-title":"Fasting Induces Hyperlipidemia in Mice Overexpressing PCSK9: Lack of Modulation of VLDL Hepatic Output by the LDLr","volume":"147","author":"Lambert","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib107","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/ATVBAHA.108.164541","article-title":"Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib108","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.febslet.2008.02.038","article-title":"Activation of the farnesoid X receptor represses pcsk9 expression in human hepatocytes","volume":"19","author":"Langhi","year":"2008","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib109","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/83799","article-title":"Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption","volume":"27","author":"Lee","year":"2001","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib110","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1194\/jlr.M500018-JLR200","article-title":"ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice","volume":"46","author":"Lee","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib111","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0022-2275(20)32360-9","article-title":"Differential expression of ACAT1 and ACAT2 among cells within liver, intestine, kidney, and adrenal of nonhuman primates","volume":"41","author":"Lee","year":"2000","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib112","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00010.2008","article-title":"Role of bile acids and bile acid receptors in metabolic regulation","volume":"89","author":"Lefebvre","year":"2009","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib113","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1194\/jlr.M800375-JLR200","article-title":"Identification of mRNA binding proteins that regulate the stability of LDL receptor mRNA through AU-rich elements","volume":"50","author":"Li","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.bbalip.2008.01.001","article-title":"Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL TG and ApoB secretion in mice","volume":"1781","author":"Liu","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib115","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbalip.2007.05.001","article-title":"Activation of the hepatic LDL receptor promoter by thyroid hormone","volume":"1771","author":"Lopez","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib116","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1001\/jama.260.5.641","article-title":"Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study","volume":"260","author":"Manninen","year":"1988","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib117","doi-asserted-by":"crossref","first-page":"G645","DOI":"10.1152\/ajpgi.00299.2007","article-title":"Development and physiological regulation of intestinal lipid absorption. II. Dietary lipid absorption, complex lipid synthesis, and the intracellular packaging and secretion of chylomicrons","volume":"293","author":"Mansbach","year":"2007","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib118","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib119","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0006-291X(02)02550-0","article-title":"Identification of membrane-type receptor for bile acids (M-BAR)","volume":"298","author":"Maruyama","year":"2002","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib120","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1194\/jlr.R800061-JLR200","article-title":"The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis","volume":"50","author":"Masson","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib121","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib122","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.amjcard.2007.09.095","article-title":"Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study)","volume":"101","author":"May","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib123","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.97.8.4245","article-title":"High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1","volume":"97","author":"McNeish","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib124","doi-asserted-by":"crossref","first-page":"10561","DOI":"10.1074\/jbc.M808802200","article-title":"Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells","volume":"284","author":"McNutt","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib125","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jama.301.11.1131","article-title":"ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial","volume":"301","author":"Meuwese","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib126","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1038\/sj.emboj.7601769","article-title":"Identification of a VLDL-induced, FDNPVY-independent internalization mechanism for the LDLR","volume":"26","author":"Michaely","year":"2007","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib127","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1056\/NEJM199511163332002","article-title":"Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population","volume":"333","author":"Miettinen","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib128","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/01.ATV.20.5.1340","article-title":"Noncholesterol sterols and cholesterol lowering by long-term simvastatin treatment in coronary patients: relation to basal serum cholestanol","volume":"20","author":"Miettinen","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib129","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/oxfordjournals.aje.a115479","article-title":"Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population","volume":"131","author":"Miettinen","year":"1990","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study","volume":"157","author":"Mohiuddin","year":"2009","journal-title":"Am Heart J"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib131","doi-asserted-by":"crossref","first-page":"37229","DOI":"10.1074\/jbc.M206749200","article-title":"Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA","volume":"277","author":"Nakahara","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib132","doi-asserted-by":"crossref","first-page":"20709","DOI":"10.1016\/S0021-9258(19)36836-X","article-title":"The p27 catalytic subunit of the apolipoprotein B mRNA editing enzyme is a cytidine deaminase","volume":"268","author":"Navaratnam","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib133","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0021-9150(00)00653-5","article-title":"Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread","volume":"156","author":"Neil","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib134","first-page":"19454765","article-title":"Influence of class B scavenger receptors on cholesterol flux across the brush border membrane and intestinal absorption","author":"Nguyen","year":"2009","journal-title":"J Lipid Res PMID"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.bjp.0705332","article-title":"Lipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro","volume":"139","author":"Nishimoto","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib136","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2007.05.005","article-title":"Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs","volume":"223","author":"Nishimoto","year":"2007","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib137","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.bcp.2003.08.011","article-title":"Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors in human myocytes","volume":"66","author":"Nishimoto","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib138","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1001\/jama.297.12.1362","article-title":"Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials","volume":"297","author":"Nissen","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib139","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMoa054699","article-title":"Effect of ACAT inhibition on the progression of coronary atherosclerosis","volume":"354","author":"Nissen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib140","doi-asserted-by":"crossref","first-page":"29D","DOI":"10.1016\/j.amjcard.2005.03.017","article-title":"Comparison of efficacy of plant stanol ester and sterol ester: short-term and longer-term studies","volume":"96","author":"O'Neill","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib141","doi-asserted-by":"crossref","first-page":"E911","DOI":"10.1152\/ajpendo.00328.2001","article-title":"Gastrointestinal absorption and plasma kinetics of soy Delta(5)-phytosterols and phytostanols in humans","volume":"282","author":"Ostlund","year":"2002","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib142","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1161\/01.CIR.0000143163.76212.0B","article-title":"ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver","volume":"110","author":"Parini","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib143","unstructured":"Perez, A., Kupfer, S., Chen, Y., & Law, R. (2006). in Abstract 675: Addition of TAK-475 to atorvastatiin provides incremental benefits. In (pp. 114:II-113-II_144)."},{"key":"10.1016\/j.pharmthera.2010.02.006_bib144","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1016\/j.atherosclerosis.2006.10.036","article-title":"Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients","volume":"194","author":"Pisciotta","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib145","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1194\/jlr.M500272-JLR200","article-title":"Plant sterols and stanols: effects on mixed micellar composition and LXR (target gene) activation","volume":"46","author":"Plat","year":"2005","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib146","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.ejcn.1601071","article-title":"Effects on serum lipids, lipoproteins and fat soluble antioxidant concentrations of consumption frequency of margarines and shortenings enriched with plant stanol esters","volume":"54","author":"Plat","year":"2000","journal-title":"Eur J Clin Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib147","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1053\/j.gastro.2003.10.074","article-title":"Sitosterolemia in ABC-transporter G5-deficient mice is aggravated on activation of the liver-X receptor","volume":"126","author":"Plosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib148","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1093\/jn\/136.8.2135","article-title":"Reduction of cholesterol absorption by dietary plant sterols and stanols in mice is independent of the Abcg5\/8 transporter","volume":"136","author":"Plosch","year":"2006","journal-title":"J Nutr"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib149","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0092-8674(87)90510-1","article-title":"A novel form of tissue-specific RNA processing produces apolipoprotein-B48 in intestine","volume":"50","author":"Powell","year":"1987","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib150","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1161\/ATVBAHA.109.188581","article-title":"Control of ACAT2 liver expression by HNF4{alpha}: lesson from MODY1 patients","volume":"29","author":"Pramfalk","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib151","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib152","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1172\/JCI0215387","article-title":"Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype","volume":"110","author":"Pullinger","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib153","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI6576","article-title":"Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice","volume":"103","author":"Raabe","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib154","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib155","doi-asserted-by":"crossref","first-page":"18793","DOI":"10.1074\/jbc.M109927200","article-title":"Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta","volume":"277","author":"Repa","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib156","doi-asserted-by":"crossref","first-page":"30C","DOI":"10.1016\/0002-9149(84)90854-3","article-title":"Lipid Research Clinics Coronary Primary Prevention Trial: results and implications","volume":"54","author":"Rifkind","year":"1984","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib157","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib158","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/hmg\/2.12.2109","article-title":"Abetalipoproteinemia is caused by defects of the gene encoding the 97kDa subunit of a microsomal triglyceride transfer protein","volume":"2","author":"Shoulders","year":"1993","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib159","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.febslet.2004.04.026","article-title":"The farnesoid X receptor induces very low density lipoprotein receptor gene expression","volume":"566","author":"Sirvent","year":"2004","journal-title":"FEBS Lett"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib160","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1073\/pnas.0400441101","article-title":"Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport","volume":"101","author":"Smart","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib161","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.106.174516","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute","volume":"113","author":"Smith","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib162","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature03121","article-title":"Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs","volume":"432","author":"Soutschek","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib163","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjcard.2004.05.021","article-title":"Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I","volume":"94","author":"Superko","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib164","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1272\/jnms.74.338","article-title":"Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia","volume":"74","author":"Suzuki","year":"2007","journal-title":"J Nippon Med Sch"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib165","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1194\/jlr.M800553-JLR200","article-title":"The thyromimetic T-0681 protects from atherosclerosis","volume":"50","author":"Tancevski","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib166","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1194\/jlr.M800439-JLR200","article-title":"Genetic inactivation of NPC1L1 protects against sitosterolemia in mice lacking ABCG5\/ABCG8","volume":"50","author":"Tang","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib167","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1161\/01.CIR.0000147777.12010.EF","article-title":"Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions","volume":"110","author":"Tardif","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib168","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib169","doi-asserted-by":"crossref","first-page":"47594","DOI":"10.1074\/jbc.M308235200","article-title":"Compared with Acyl-CoA:cholesterol O-acyltransferase (ACAT) 1 and lecithin:cholesterol acyltransferase, ACAT2 displays the greatest capacity to differentiate cholesterol from sitosterol","volume":"278","author":"Temel","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib170","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1172\/JCI30060","article-title":"Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe","volume":"117","author":"Temel","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib171","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.amjcard.2008.10.029","article-title":"Comparison of efficacy and safety of atorvastatin (80mg) to simvastatin (20 to 40mg) in patients aged <65 versus>or=65years with coronary heart disease (from the Incremental DEcrease through Aggressive Lipid Lowering [IDEAL] study)","volume":"103","author":"Tikkanen","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib172","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1194\/jlr.P800061-JLR200","article-title":"Effects of ezetimibe and simvastatin, coadministered and alone, on the in vivo kinetics of APOB-48 and APOB-100 in men with mixed hyperlipidemia","volume":"50","author":"Tremblay","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib173","first-page":"19738285","article-title":"Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 (PCSK9) levels","author":"Troutt","year":"2009","journal-title":"J Lipid Res PMID"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib174","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib175","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ctim.2005.08.003","article-title":"Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration","volume":"13","author":"Ulbricht","year":"2005","journal-title":"Complement Ther Med"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib176","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/abbi.1998.0704","article-title":"Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A","volume":"355","author":"Vaidya","year":"1998","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib177","doi-asserted-by":"crossref","first-page":"28103","DOI":"10.1074\/jbc.M504609200","article-title":"Caveolin-1 is not required for murine intestinal cholesterol transport","volume":"280","author":"Valasek","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib178","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1161\/ATVBAHA.108.171363","article-title":"Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice","volume":"28","author":"van der Hoorn","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib179","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(01)00825-1","article-title":"The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys","volume":"415","author":"Van Heek","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib180","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0022-3565(24)36992-7","article-title":"In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461","volume":"283","author":"Van Heek","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib181","doi-asserted-by":"crossref","first-page":"10D","DOI":"10.1016\/j.amjcard.2005.03.014","article-title":"Cholesterol and plant sterol absorption: recent insights","volume":"96","author":"Von Bergmann","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib182","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1152\/ajpendo.2001.280.3.E540","article-title":"Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production","volume":"280","author":"Wang","year":"2001","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib183","doi-asserted-by":"crossref","first-page":"E271","DOI":"10.1152\/ajpendo.90920.2008","article-title":"Lipoprotein lipase: from gene to obesity","volume":"297","author":"Wang","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib184","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2008.03.011","article-title":"Effect of ezetimibe on the prevention and dissolution of cholesterol gallstones","volume":"134","author":"Wang","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib185","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1161\/ATVBAHA.108.175224","article-title":"Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism","volume":"28","author":"Watts","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib186","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0002-8223(21)05668-6","article-title":"Sterol content of foods of plant origin","volume":"73","author":"Weihrauch","year":"1978","journal-title":"J Am Diet Assoc"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib187","doi-asserted-by":"crossref","first-page":"11140","DOI":"10.1073\/pnas.0800936105","article-title":"Extracellular loop C of NPC1L1 is important for binding to ezetimibe","volume":"105","author":"Weinglass","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib188","doi-asserted-by":"crossref","first-page":"4945","DOI":"10.1210\/en.139.12.4945","article-title":"Thyroid hormone action on liver, heart, and energy expenditure in thyroid hormone receptor beta-deficient mice","volume":"139","author":"Weiss","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib189","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1126\/science.1439810","article-title":"Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia","volume":"258","author":"Wetterau","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib190","doi-asserted-by":"crossref","first-page":"9800","DOI":"10.1016\/S0021-9258(19)38742-3","article-title":"Protein disulfide isomerase is a component of the microsomal triglyceride transfer protein complex","volume":"265","author":"Wetterau","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib191","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/0005-2760(86)90084-6","article-title":"Localization of intracellular triacylglycerol and cholesteryl ester transfer activity in rat tissues","volume":"875","author":"Wetterau","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib192","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/emboj\/17.2.455","article-title":"Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1","volume":"17","author":"Wikstrom","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib193","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0022-2275(20)37252-7","article-title":"Modulation of LDL receptor mRNA stability by phorbol esters in human liver cell culture models","volume":"38","author":"Wilson","year":"1997","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib194","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0022-2275(20)33870-0","article-title":"Stabilization and cytoskeletal-association of LDL receptor mRNA are mediated by distinct domains in its 3\u2032 untranslated region","volume":"39","author":"Wilson","year":"1998","journal-title":"J Lipid Res"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib195","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1152\/physrev.2001.81.3.1097","article-title":"Physiological and molecular basis of thyroid hormone action","volume":"81","author":"Yen","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib196","doi-asserted-by":"crossref","first-page":"6616","DOI":"10.1074\/jbc.M511123200","article-title":"Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake","volume":"281","author":"Yu","year":"2006","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib197","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/0003088-200948010-00003","article-title":"Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2\u2032-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe","volume":"48","author":"Yu","year":"2009","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib198","doi-asserted-by":"crossref","first-page":"16237","DOI":"10.1073\/pnas.252582399","article-title":"Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion","volume":"99","author":"Yu","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib199","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1172\/JCI0216001","article-title":"Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol","volume":"110","author":"Yu","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/hep.20783","article-title":"Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice","volume":"42","author":"Yu","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib201","doi-asserted-by":"crossref","first-page":"15565","DOI":"10.1074\/jbc.M301311200","article-title":"Stimulation of cholesterol excretion by the liver X receptor agonist requires ATP-binding cassette transporters G5 and G8","volume":"278","author":"Yu","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib202","doi-asserted-by":"crossref","first-page":"18602","DOI":"10.1074\/jbc.M702027200","article-title":"Binding of PCSK9 to EGF-A repeat of LDL receptor decreases receptor recycling and increases degradation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib203","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clinthera.2007.01.003","article-title":"Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes","volume":"29","author":"Zieve","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharmthera.2010.02.006_bib204","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nature04688","article-title":"RNAi-mediated gene silencing in non-human primates","volume":"441","author":"Zimmermann","year":"2006","journal-title":"Nature"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810000562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725810000562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:00:28Z","timestamp":1739970028000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725810000562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":204,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0163725810000562"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2010.02.006","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}